Skip to contentC
Capricor Therapeutics, Inc.
C
CAPRCapricor Therapeutics, Inc. Q2 2018 · 10-Q
Revenue$403.96K$403.96K−59.5% vs Q2 2017 Net Income-$4.12M-$4.12MN/M vs Q2 2017 EPS Diluted-$1.42-$1.42N/M vs Q2 2017 Operating Income-$4,163,008N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Capricor Therapeutics, Inc. · CIK 1133869 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,691,651N/M Margins · derivedOperating margin-1030.5%−691.5 pt vs Q2 2017
Net margin-1020.8%−672.3 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 13, 2018 · 44 d after period end